IP Library Granted Patent US 8,962,913
Granted Patent B2
US 8,962,913 · App. 13/795,765 · Granted Feb 24, 2015

Humanized IL-7 rodents

Inventor: Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278C07K14/5418A01K2217/052A01K2217/07A01K2217/072A01K2227/105A01K2267/0331A01K2267/0387A01K2267/0393
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,913
App. No.
13/795,765
Granted
Feb 24, 2015
Kind
B2
Abstract

Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences.

Claims (6)

1. A mouse whose genome comprises a replacement of at least mouse IL-7 exons 2, 3, 4, and 5 with a human genomic segment comprising human IL-7 exons 2, 3, 4, 5, and 6 to form a human or humanized IL-7-encoding gene, wherein the replacement is at an endogenous mouse IL-7 locus, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory elements, and wherein the mouse comprises human or humanized IL-7 in serum at a level that is about the same level of endogenous mouse IL-7 in serum of an age matched wild-type mouse.

2. The mouse of claim 1 , wherein the level is about 2.4 to about 3.2 pg/mL.

3. The mouse of claim 1 , wherein said replacement forms a human IL-7-encoding gene, and wherein the mouse comprises human IL-7 in serum at a level that is about the same level of endogenous mouse IL-7 in serum of an aged-matched wild-type mouse.

4. A method for making a mouse with a human or humanized IL-7-encoding gene, comprising modifying the genome of a mouse by replacing at the endogenous mouse IL-7 gene locus at least mouse exons 2, 3, 4 and 5 of the endogenous mouse IL-7-encoding gene with a human genomic segment comprising human IL-7 exons 2, 3, 4, 5, and 6 to form a human or humanized IL-7-encoding gene, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences, and wherein the mouse comprises human or humanized IL-7 in serum at a level that is about the same level of endogenous mouse IL-7 in serum of an aged-matched wild-type mouse.

5. The method of claim 4 , wherein the level is about 2.4 to about 3.2 pg/mL.

6. The method of claim 4 , wherein said human or humanized IL-7 gene encodes human IL-7, and wherein the mouse comprises human IL-7 in serum at a level that is about the same level of endogenous mouse IL-7 in serum of an aged-matched wild-type mouse.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2013
From: MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 030433/0378 →
Continuity (3)
Provisional Application 61660976 · Jun 18, 2012
Provisional Application 61740074 · Dec 20, 2012
Related Publication 20130340104A1 · Dec 19, 2013